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INTRODUCTION
Colorectal carcinoma accounts for the
majority of all gastrointestinal cancers and is the
second leading site of cancer, excluding skin
cancers, in overall incidence in the United
States. 1 Cancer of the stomach, although decreasing in frequency, is still an important cause
of morbidity and mortality. Unfortunately, data
from large numbers of patients such as can be
found in Cancer Patient Survival Report No. 5
show only very modest increases in survival for
patients with th\;!Se diseases in recent years. 2
Gastric Carcinoma
Most patients who develop gastric cancer
have regional or distant disease at diagnosis.
The presence of regional nodal involvement is
almost synonymous with incurability since virtually all these patients are either non-resectable
at the tim(;l of operation or rapidly develop systemic recurrences. Any improvement in treatment results would be expected to be produced
by chemotherapy or immunotherapy rather than
from localized forms 9f treatment.
Fortunately, gastric carcinoma is relatively
responsive to chemotherapeutic treatment, and
at least four drugs have now been identified as
active in treatment of this condition, namely 5fluorouracil (5-FU), Adriamycin, mitomycin-C,
and semustine (methyl-CCNU). Although semustine is the nitrosourea that has been most
extensively used in the chemotherapy of gastrointestinal neoplasms, it is still an investigational
drug and therefore is not always conveniently
available. Other nitrosoureas that are on the
market are probably similar in activity.
Percentage of response and increase in
survival with single-drug therapy have been
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modest, and for this reason the drugs have
been combined into a variety of multiple-drug
regimens . Most of the possible two and threedrug combinations of the four active drugs have
been tried.
Table 1 shows response rates and survival figures for some of the most extensively
tested combinations. The combination of 5-FU
and semustine was one of the first advocated as
being superior to 5-FU alone in the treatment of
gastric carcinoma. More recently 5-FU plus
Adriamycin plus mitomycin-C (FAM) combinations have become more popular. The FAM
regimen was initially reported to have a 50% response rate in gastric carcinoma. The most recent update of over 60 patients indicates that
the response rate is holding at approximately
43%. 3
The FAM regimen (Table 2) is a well-tolerated treatment which gives partial or complete
responses in about one half of the patients and
benefits other patients by stabilizing the disease, resulting in prolonged survival for the population of treated patients. Quality of survival for
many is good, and it is not uncommon to see
responses lasting for over one year.
One problem with the treatment is cumulative marrow toxicity which is attributed to
the mitomycin-C in the regimen . This tends to
limit the treatment that can be given after the
first few cycles. The cycles of treatment are similar to other day-1 , day-8 treatments given every
eight weeks.
Other combinations of these drugs which
utilize different doses and regimens have also
been tried. Two of these used at the Sloan Kettering Institute known as MIFA I and MIFA II con~
firm that these drugs in combination are effec-
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TABLE 1
Combinations Used in Treatment of Gastric Carcinoma

5-FLUOROURACIL + Semustihe
5-FLUOROURACIL + ADRIAMYCIN + MITOMYCIN-C
5-FLUOROURACIL + ADRIAMYCIN + Semustine
5-FLUOROURACIL + MITOMYCIN-C
ADRIAMYCIN + MITOMYCIN-C

tive in the treatment of gastric cancer. 4 Table 1
indicates treatment results of these and other
combination treatments for gastric cancer. The
median survival of patients with untreated advanced gastric carcinoma is four months or
about 1 7 weeks from diagnosis . Since the figures in Table 1 show the survival in weeks from
the time of treatment rather than diagnosis for
the entire population of treated patients, not just
the responders, one can see that a doubling of
the survival time for the better combination is
achievable .
Dr Charles Moertel from the Mayo Clinic
has recently analyzed data combined from several cooperative groups. Using a statistical
model, he concluded that 5-FU and Adriamycin
contribute most to the treatment of gastric cancer. 5 This is a combination that has not received
extensive use, and the projected value of the
treatment needs confirmation in a large clinical
trial.

Colorectal Carcinoma
Although there have been a number of attempts to improve results in treatment of colorectal cancer, most of these have been futile or
have achieved only very modest success. The
surgical treatment of colorectal cancer has
been standard for several decades, and although some recent studies indicate that pre-

TABLE 2
FAM Regimen
DAY 1
F
A
M

DAY 8
F

DAY 29

DAY 36

F
A

F

F = 5-Fluorouracil
600 mg/M 2
A= Adriamycin
30 mg/M 2
M = Mitomycin-C
1 O mg/M 2
Cycles of treatment are repeated every eight weeks.

Response Rate

Med. Survival Weeks

9-45%
21-43%
36%

24-34
22-30

17-25

17

operative ahd postoperative radiation therapy
given adjuvantly in high-risk patients would be
beneficial , particularly in patients with carcinoma of the rectum, these suggestions have not
met with widespread acceptance.
Five-fluorouracil has been a standard
treatment for colorectal cancer for 20 years ,
and one might summarize the clinical experience of a number of investigators' attempts to
improve results by manipulating the 5-FU dose,
schedule, or route of administration by simply
stating that no schedule of treatment has been
definitely shown to be superior to any other. 6
The most common schedules used have been
daily intravenous. treatments for five days repeated at five-week intervals or one intravenous
treatment administered weekly .
Administered orally , 5-FU gives response
rates similar to the intravenous treatments of the
drug . However, Moertel 7 has reported that the
duration of response is shorter with the oral
form of treatment. Absorption is erratic, averaging about 50%. Because of these facts and because no oral form of treatment has been marketed, use of this drug by this route of
administration has not gained wide acceptance.
Response rates with 5-FU in colorectal
carcinoma average approximately 20%. Two
forms of therapy which have a response rate
above 1 0% are the nitrosoureas and mitomycin-C . Other drugs have either had limited use
in colorectal cancer or have given response
rates of 1 0% or less, leaving only a few drugs
that have a significant response rate in this disease.
A number of combinations have been devised for the treatment of colorectal carcinoma,
the more extensively tested combinations
being : 5-FU with semustine, mitomycin-C or hydroxyurea; 5-FU plus semustine plus vincristine;
and 5-FU plus semustine plus dacarbazine . Response rates for the combinations were initially
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reported to exceed the results of 5-FU alone.
The combination of 5-FU, semustine and vincristine has been said to have response rates in
the range of 35 to 40% by at least three different groups. 8 •9 · 10 However, as additional studies
and survival data are reported, the superiority of
this combination over 5-FU alone has not been
confirmed .6
Median survival for patients after proof of
incurability is approximately 30 to 32 weeks
with 5-FU alone, anq for the combinations the
survival has be.en in the same range . Consequently, the current consensus is that no
combination of drugs for the treatment of colorectal carcinoma has proved to be superior to 5FU alone. At this time other combinations are
being tried which , it is hoped , will yield results
surpassing those with only 5--FU.
There is controversy regarding whether or
not 5-FU alone increases survival in patients
with colorectal carcinoma. To my knowledge,
no prospective randomized trials have been
done comparing 5-FU with no treatment in patients with advanced disease. Used many years
ago for the treatment of advanced colorectal
cancer, 5-FU was shown to yield responses and
was felt to be beneficial , not only in achieving
these responses but also in extenc;jing the life of
the patient. No 9ne has since been willing to
compare it to no treatment.
One can easily demonstrate that 5-FU responders live longer than non-responders. Additionally, retrospective analysis indicates that
5-FU produces a modest increase in median
survival in a population of treated patients.
Moertel' s own data 1 1 demonstrated that 5-FU
treated patients live longer throughout the entire
survival curve than matched historical controls.
This difference was discounted by Moertel who
stated that there is no evidence showing that 5FU prolongs survival , attributing the difference
to patient selection . This is only an opinion, and
different interpretations are possible.
A number of surgical adjuvant trials have
been conducted in patients with colon and rectal carcinomas. One of the earliest studies utilized thiotepa or fluorodeoxyuridine (FUdR) after
surgery. This particular study showed no effect.
However, it is of interest that these patients, followed over a decade, had no increase in carcinogenicity or other lc;3.te toxicity which could be
ascribed to those treatments. 12 More recentiy a
number of studies have been done utilizing 5-

FU in adjuvant treatment. In the non-randomized studies using historical controls , 5-FU was
reported to produce a beneficial effect 1 3 · 14 ; in
the randomized studies the 5-FU , in all cases,
produced a slight prolongation of disea$e-free
interval and survival in the treated group. 15 - 19
lnitialiy, the difference was judged not to be statistically significant; however, a recent statistical
analysis using cumulative results involving
larger patient numbers resulted in the conclusion that there is a statistically significant improvement, at least for some subsets of 5-FUtreated patients in the adjuvant setting. Results
of these studies are still pending .
In an article in the Annals of Internal Medicine,20 Ors Weiss and Devita stated that at the
present time whether or not a patient receives
adjuvant chemotherapy for colorectal carcinoma is a decision that needs to be individualized for each patient. This is primarily because the results of 5-FU have been marginal at
best, and the potential benefits of therapy may
be overridden by a variety of other factors: disease stage (patients with Duke 's 82 or C stage
lesions, eg, extension through the muscular
layer and / or invoived nodes are customarily
treated); age of the patient; histologic grade of
the tumor; economic factors ; and convenience
of travel to the treatment center for the patient.
Following a trial of adjuvant treatment, the decision to continue treatment should be based on
the patient's tolerance tempered by the knowledge of limited survival benefit .

Other Gas\rointestinal Tumors
There are three uncommon types of gastrointestinal malignancies, all of which show significant response rates to treatment with chemotherapy.
Leiomyosarcomas are found in the stomach and in the bowel . Recurrent or metastatic
tumors respond to treatment with Adriamycin in
approximately 30% of cases, and if combined
with dacarbazine, the response rate may be
1 0% higher. The treatment for metastatic
leiomyosarcomas of the bowel is the same as
for other metastatic sarcomas.
Lymphomas also occur in the gastrointestinal tract, and although their natural history
may be somewhat different from those originating els~where, the chemotherapeutic treatment
is basically similar. Where the histology predicts
a favorable outcome, treatment would probably
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consist of cyclophosphamide plus vincristine
plus prednisone (COP) therapy and the unfavorable ones treated in addition with Adriamycin
and possibly with Bleomycin .
Carcinoid tumors are also responsive to
chemotherapeutic treatment. About one third of
these patients with advanced disease show objective responses to treatments with 5-FU and
streptozotocin in combination. More recently
Adriamycin has been used as a single agent.
Treatment for this condition is still very much in
a stage of evolution .

Other Advances
The biologic marker known as carcinoembryonic antigen (CEA) which has been developed for clinical use in the last decade, ~as
contributed materially to our ability to stage and
follow patients with colorectal carcinoma. The
initial hope was that the test would be useful as
a diagnostic and screening tool. It has not
proved to be very useful for this purpose . However, it has been found to be beneficial as a
prognostic indicator. Patients with high levels of
CEA prior to surgery will not do as well as patients with normal levels. It can also be utilized
to assess adequacy of treatment or to evaluate
disease recurrence and treatment response. It
has been suggested that CEA-producing tumors are inherently more likely to metastasize
and are less controllable by the body's immune
processes. This biological difference, if confirmed , will undoubtedly influence future treatment strategies .
Table 3 presents data taken from a study
where 2, 3 7 2 patients of an unselected population were screened for malignancy using CEA
values. 2 1 Seventy-three of these patients were
TABLE 3
Use of CEA In Screening an Unselected Populatlon21
23 72 people followed 5 years
87% False Positive 64% False Negative
CEA LEVEL
::::5 ng / ml
< 5 ng/ml
Developed a
CEA related Cancer

16

11*

Never developed
Cancer

2000+

62

25

73
(3 % of total population)
• two others were found to have incidental cancers not
related to CEA evaluation.

found to have elevated CEA levels above 5 ng /
ml. Workup of these 73 patients resulted in the
finding of malignancy in only 11 patients . Nine
had a CEA-related malignancy and two had an
incidental malignancy. The false-positive rate ,
therefore, was calculated at 87% .
More disturbing than even the high falsepositive rate was the fact that 1 6 patients who
were CEA-negative developed a CEA-associated cancer during the follow-up period for a
false-negative rate of 64% . Only 3% of the
2, 3 7 2 patients had elevated CEA levels which
is consistent with the fact that 95% of a normal
population are known to have CEA below 2. 5
ng / ml. (In this population , 97% had the CEA
level below 5 ng / ml.) The low incidence of cancer in this population of 2 ,3 7 2 resu lted in the
high false-negati ve percentage . CEA testing
may play a role in screening certain high-risk
populations , but it is not suitable as a screening
mechanism for carcinoma of the colon in unselected populations.
It was originally thought that CEA would
be specific for colon carcinoma since the antigen was obtained from fetal colonic ti ssue .
However, it was soon found that it is non-specific for colon carcinoma, being elevated in a
variety of other malignancies including breast,
lung , pancreas , stomach and bladder carcinomas, and in other malignancies. CEA is also
elevated in patients with liver disease, pancreatic cysts, gastrointestinal polyps and other benign conditions . The CEA is not specific for a
particular primary site and is not even as specific as one would like for malignancy .
With the understanding of certain characteristics of biologic markers shown in Table 4,
CEA tests can be used quite advantageously for
a number of purposes . In general , biologic
markers are non-specific for histologic types of
neoplasms and often are not even specific for
malignancy. The specificity and sensitivity tend
to be inversely related . By developing a more
sensitive assay, more positive resu lts will be obtained in patients with non-malignant conditions
or with tumor types other than those anticipated . In contrast , if normal levels are drawn at
a higher concentration, the test is more specific .
For example, most patients with CEA over 1 0
ng/ml will have a malignancy.22 The percentage of patients with positive markers increases
with the stage of the disease. Reports of CEA
elevation in the 9 0% range are applicable only
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TABLE 4
Some Characteristics of Biologic Markers
1 . In general biologic markers are non-specific for a
histologic type of neoplasm and often are not even specific
for malignancy.
2. Sensitivity and specificity tend to be inversely related.
3. The percentage of patients with positive markers
increases with stage of disease.
4. Not all patients develop positive markers.
5. Marker status is not a dependent variable in relatipn to
staging .

to patients with advanced colorectal carcinoma.
The figure is much lower for patients with localized or regional disease only.
Not all patients develop positive markers.
Only those patients with certain phenotypic cancer cell expressions will show marker elevation .
Other patients having histologically-similar tumors will never be marker positive. Therefore, it
is futile to attempt to manipulate a test to give
results 1 00% of the time or to look for new
markers that will do this.
The percentage of CEA positivity in patients with colonic cancer was initially reported
in excess of 90%. Later the percentage fell, the
reason being that initially patients with advanced disease were tested , and in the later series more patients with earlier stages of disease
were tested .2 3 The percentage of CEA elevation
directly correlates with the stage of disease;
however, it is not a dependent variable, meaning that the distribution of CEA positives in patients of various stages has a tendency toward
randomness. In general, CEA and other biologic markers are not dependent variables in relation to the stage of disease or any other
known prognostic factor. This means that prognostication is improved by considering marker
values along with stage, grade of tumor and
other standard prognostic indicators.
CEA is also useful in following colorectal
patients for recurrence. The majority of patients
who are found to have recurrences will have
shown at least one CEA elevation greater than
2 .5 ng/ml more than three months before documentation of recurrence. One study 2 4 showed
54% of the patients having this marker positive
(>2 .5 ng/ml) more than three months prior to
the documentation of recurrence. If a higher
positive value (5 ng/ml) is used , 41 % will have
an elevation three months before clinical tumor
recurrence . An additional number of patients
will have markers positive for three months or

less prior to recurrence. The percentage of patients who show elevated CEA prior to recurrence of colon cancer is higher than in rectal
cancer. (Table 5).
In colon cancer only 14% are never elevated prior to documentation of recurrence
compared to 32% for rectal cancer. While this
looks quite good as a tool for predicting recurrences, it has to be tempered by the fact that
matched controls also have a high percentage
of at least one elevated CEA value. The
matched controls were patients with the same
age, the same disease, and treatment, who had
not had a recurrence during periods of equal
follow-up. Some of these patients will eventually
turn out to have a recurrence because it is
known that the CEA can be elevated for as long
as several years prior to recurrence. Some of
these patients have random increases in CEA
value; others have benign causes of the elevation.
It is known that patients who receive blood
products at the time of their surgery sometimes
develop CEA elevations that plateau and later
decrease2 5 secondary to hepatitis or undetermined factors in the absence of acute or
chronic liver disease. The problem in following
these patients is to separate those who have
random elevations or benign conditions from
those who have a recurrence of malignancy. In
order to distinguish those with random elevations, a CEA nomogram has been developed to
indicate when values are statistically increased .
Nomograms are published in the literature,26 · 2 7
but to be valid , each laboratory should construct its own based on the precision of its test.
While the nomogram is useful in differentiating
patients who have a random increase from
those with a true increase in CEA levels, repeating the value several times helps in making this
differentiation .
It is important to make a diagnosis of recurrence earlier using CEA elevations. Some of
these patients may be candidates for second
surgery; others will be candidates for radiation
therapy or chemotherapy. In considering possible patients for second surgery, it is necessary
to separate those patients who are going to
have an operable malignancy from those who
have random fluctuation of the CEA , benign
conditions, and inoperable lesions. Using the
nomogram, one can distinguish most random
fluctuations . Benign conditions tend to be
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TABLE 5
Percentage of Patients With
Established Tumor Recurrence Who Exhibit
CEA Elevations 24
Primary
Tumor
Site
COLON
RECTUM
COMBINED

>2 .5 ng / ml
>3 mos before
recurrence

>5 ng/ml
>3 mos before
recurrence

>2.5 ng / ml
<3 mos before
recurrence

>5 ng / ml
<3 mos before
recurrence

58
42
54

45
31
41

28
26
29

26
32
28

nomogram positive as are both operable and inoperable malignancies. The operable malignancies and random fluctuations would not be
expected to have elevated liver enzymes. The
degree of CEA elevation helps to discern the
operable and inoperable malignancies. High
elevations correlate with metastatic disease and
more specifically with liver metastases.
To determine operable cases one looks
for patients with minimal elevations of CEA. In
one series the mean elevation in the operable
patients was 6.5 ng/ml compared to 15 .5 ng /
ml in those who had inoperable malignancy.28
Additional information can be gained by looking
at the character of the rise . If a benign condition
exists, the CEA tends to plateau at levels usually less than 1 0 ng/ml. For any type of malignant condition, an exponential rise occurs ; the
slope of the rise for those who are operable is
less than that for the inoperable ones. The value
is probably in the range of 0.5 ng/ml / mo or
less for operable cancers and >1 ng/ml/mo
for inoperable patients.29

Never
elevated
14
32

17

A factor to be considered in the decision
for reoperability is the interval between surgery
and observed CEA elevation . The benign causes
of the CEA elevations occur earlier after surgery
than the operable malignancies .21 Any CEA elevations that occur early are more likely to be associated with inoperability. If they are caused by
tumor , they probably are rising at a more rapid
rate than those that occur later. Patients whose
CEA elevations occur more than five months after surgery are more likely to be eligible for reexploration . These factors are summarized in
Table 6.
It is important to stress that the decision
regarding reoperation is not based on just the
CEA level. A careful determination must be
made that the patient does not have clin ical
metastatic disease by obtaining a chest x-ray ,
liver scan, serum chemistries , and other appropriate tests such as sonography, abdominal CT
scan , and liver biopsy if other tests are negative . Careful monitoring and testing will exclude
five sixths of the patients for consideration for

TABLE 6
Differential Diagnosis of CEA Elevation

Nomogram

Liver
Enzymes

Random
Fluctuation

- or±

-

Benign
Condition

+

+

+

-

Cause of CEA
Elevation

Operable
Malignancy
Inoperable
Malignancy

Often

Often

++

+

Degree of
Elevation
Depends on
Baseline Value
Usually
<1 Ong / ml
Mean
6.5 ng / ml
mean
15.5ng/ ml

Character
of Rise

Time of
Occurrence
Post-Resection
Random

Not
Verifiable
Non
Exponential
(Plateau)
Exponential
Slope
<1 ng / ml / mo
Exponential
Slope
> 1 ng / ml / mo

Median Time
<5mo.

)

Median Time
>5mo.
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"second-look" surgery. Of the remaining one
sixth, the resectability rate may be as high as
30%. 30 Increasing the percentage of patients
operated on will decrease the resectability percentage . The cure rate for the patients who are
resected a second time is not known.
A practical strategy for following patients
with colorectal cancer with CEA assays is presented. Preoperative levels should be obtained
for establishing a base line and serve as a prognostic indicator. The test should be repeated
postoperatively. Two weeks after surgery is
both convenient and appropriate; however, if
the CEA level has not returned to normal , the
test should be repeated.
Apparently not all CEA values return to
normal promptly. If they remain elevated, it is
important to establish a base line for nomogram
analysis . Subsequently, values are obtained
every two months for the early detection of recurrence . After one year the test could be run
less frequently. If a significant elevation is encountered outside the normal nomogram range ,
the test is repeated serially, two or three times,
to verify elevation and determine, if possible,
the character of the rise. Concurrently, the patient is evaluated carefully for metastatic disease. Selected patients may be candidates for
surgery.
In patients who have developed metastatic disease, CEA can be used for evaluation
of chemotherapeutic or radiotherapeutic response. The CEA appears to be more correlated with tumor burden if its value is below 1 00
ng/ml. While this correlation is sometimes erratic, it is the most valuable tool available in patients who do not have measurable disease.

CONCLUSION
Chemotherapy has produced significant
improvement in treatment results for gastric carcinoma, but to date only minimal improvement
has been achieved for colorectal carcinoma.
Earlier application of radiation therapy, specifically preoperative and postoperative radiation
therapy, particularly for patients with carcinoma
of the rectum, is sufficiently attractive for further
study.
The primary area of improvement for patients with colorectal carcinoma has been in our
ability to assess the status of the disease and in
our beginning understanding of the biologic differences in patients with the disease . Ultraso96 /

nography and CT scanning are relatively new
procedures whose effect on the overall problem
remains to be assessed . Carcinoembryonic antigen testing is clearly an important advance,
and there is every indication that other useful
markers will be developed.
The net effect of all these developments is
the increased ability to select patients accurately for given treatments and to follow treatment results more precisely. It is known from
previous experience that in those diseases in
which the assessment of results is difficult,
progress has been slow. Therefore , it is anticipated that more rapid improvements in treatments in the coming years will ultimately be reflected in the overall survival statistics of these
diseases.
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